Compare Charles River Laboratories Intl. Inc (CRL) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Wipro Limited — how do they compare? Charles River Laboratories Intl. Inc trades at $300.93 (market cap $14.23B), while Wipro Limited trades at $1.68 (market cap $16.22B). The key difference: Charles River Laboratories Intl. Inc and Wipro Limited are close in size by market cap, and Wipro Limited pays a 5.19% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Wipro Limited for 41 Days on average.
| CRL | WIT | |
|---|---|---|
Market Cap | $14.23B | $16.22B |
Volume | 1,176,885 | 9,028,667 |
Sector | Health | Technology |
52-Week High | $310.77 | $3.06 |
52-Week Low | $149.93 | $1.61 |
Typical Hold Time | 33 Days | 41 Days |
Enterprise Value | $17.06B | $14.33B |
Dividend Yield | — | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
WIT trades at $1.67, down 0.6% on the day, with a bearish technical signal from moving averages and a neutral stance from oscillators. The company reported revenue of $890.88 billion in 2025 with a net income margin of 13.92%, though recent quarters have seen earnings misses against expectations. Recent news highlights Wipro's AI initiatives boosting productivity and new cybersecurity partnerships.
The outlook is mixed; valuation ratios like a P/E of 12.78 appear reasonable, but analyst consensus is cautious with only 19% buy ratings. Key risks include competitive pressures and macroeconomic uncertainty affecting tech spending. Upside hinges on execution of AI strategies and reversing earnings misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
